Abstract CT114: FAST TIL: A more effective cell therapy product with great potential for the treatment of solid tumors

Abstract Adoptive cell therapy based on tumor-infiltrating lymphocytes (TIL-ACT) has achieved good clinical data in the treatment of solid tumors and has become a very promising treatment method for pan-solid tumors. It is extremely difficult to obtain tissue samples through surgery for patients with advanced tumors, and the disease progresses rapidly, which seriously restricts the development and commercial promotion of TIL drugs. Sino-cell Biomed's independently developed highly efficient, fully enclosed and automated FAST-TIL amplification platform, PowerTexp®, can significantly reduce the amount of tumor tissue required for TIL culture and shorten the in vitro expansion time. As of January 2025, the PowerTexp® platform has successfully completed TIL preparations for non-small cell lung cancer, breast cancer, melanoma, gastrointestinal cancers, head and neck tumors, gynecological tumors, soft tissue sarcomas, etc. The starting amount of tumor tissue required is <0.05g, the expansion success rate is > 95%, the total numbers of harvested cells reach 5×109 - 1×1011, and the cell viability is > 85%. The entire production time only takes 14 days. HS-IT101 is the first TIL product developed based on the PowerTexp® platform and is developed for pan-solid tumors. HS-IT101 has excellent quality characteristics, with the proportion of CD3+ cells > 80% and the proportion of stem cells (CD39-CD69-) > 20%. Currently, the phase I clinical trial has started for HS-IT101 (NCT06342336) since Jan 2024. Citation Format: Di Wu, Ning Li, Yu Jiang, Yongjie Wang, Xinhua Zhang, Yi Zhao. FAST TIL: A more effective cell therapy product with great potential for the treatment of solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT114.